Obesity- A Malediction In Menopause
Introduction:
Midlife, a phase marked by considerable
hormonal shifts and lifestyle changes, presents unique challenges for women,
particularly in terms of health and wellness. Obesity is one of the most
significant concerns, affecting not only physical health but also mental
well-being and general quality of life. among this essay, we will look at the
intricacies of obesity among women in their midlife, including its causes,
effects, and possible solutions.
Menopause is a seminal event produced
by the decrease of ovarian follicular activity and is diagnosed retrospectively
12 months after the permanent cessation of menstruation. The average age is 46
years. At 44.69 ± 3.79 years, Indian women enter the perimenopausal stage,
characterized by irregular periods. The menopausal transition period is
characterized by a variety of metabolic changes, including increased body
weight, total body fat, and loss of lean body mass. These changes result in
central obesity, dyslipidemia, and insulin resistance in postmenopausal women.
Obesity has been a growing epidemic for
decades. It is a well-known cause of numerous medical issues, including type 2
diabetes, hyperlipidemia, arterial hypertension, cardiovascular disease,
osteoarthritis, depression, and multiple cancers, to name a few.
The
World Health Organization defines overweight and obesity as follows:
Overweight is defined as having a BMI
of 25 kg/m2 or higher.
Obesity is defined as a BMI more than
or equal to 30 kg/m2.
Morbid obesity is defined as BMI
greater than or equal to 40 kg/m2.
Asian
population:
- Overweight -BMI between 23 and 24.9 kg/m2
- Obesity – BMI greater than 25 kg/m2
BMI is the most useful population-level
metric for both sexes and all age groups of adults. Children's age must be
taken into account when defining overweight and obesity.
Classification
and Calculation of BMI
This is a graph of BMI categories based
on the World Health Organization data.
Limitations of BMI
BMI is a commonly used and helpful
predictor of healthy body weight, however it has limits because it does not
account for body composition. The wide range of body types, as well as the
distribution of muscle, bone mass, and fat, should be considered in addition to
other parameters when calculating a person's healthy body weight. BMI is also
influenced by parameters including age, gender, ethnicity, muscle mass, body
fat, and exercise level, among others. BMI is not completely correct because it
measures extra body weight rather than excess body fat.
In adults:
For example, an elderly person who is
deemed a healthy weight but is entirely sedentary in their everyday life may
have considerable quantities of excess body fat despite not being overweight.
This would be regarded unhealthy, whereas a younger person with a higher muscle
composition and the same BMI would be deemed healthy. Athletes, particularly
bodybuilders, who are deemed overweight because muscle weighs more than fat,
may actually be at a healthy weight for their body type. Generally, according
to the CDC:
- Older persons typically have greater body fat than younger adults with the same BMI.
- Women typically have greater body fat than men with an identical BMI.
- Muscular people and highly trained athletes may have higher BMIs due to their increased muscle mass.
The risk of obesity skyrockets during the menopausal transition era. It is unclear whether this connection is due to diminishing ovarian hormone output or age. Preclinical data show that disrupting estradiol (E2) signaling via estrogen receptor (ER) deletion or ovariectomy (OVX) promotes fat formation, supporting the causal link with estrogen insufficiency. Current evidence from multiple large and long-running cohort studies, such as the Study of Women's Health Across the Nation (SWAN) and the Women's Health Initiative (WHI), suggests that the peri-menopausal increase in obesity, as assessed by body mass index (BMI), is caused by aging.
Obesity and menopausal transition
Menstrual abnormalities
precede the final menstrual period, which is caused by a dwindling pool of
ovarian follicles and variations in reproductive hormones. The Stages of
Reproductive Aging Workshop +10 (STRAW+10) criteria, which are based on menstrual
bleeding patterns, reflect a consensual staging scheme developed by field
researchers.
The menopausal transition has four
stages: late reproductive (−3), early menopausal (−2), late menopausal (−1),
and early postmenopausal (+1). During the menopausal transition, ovarian sex
steroids continue to reduce; inhibin B gradually decreases, contributing to the
relaxation of negative feedback inhibition on pituitary follicle stimulating
hormone (FSH) synthesis. In stage -3, FSH may be normal or occasionally raised,
but it continues to climb and remains persistently elevated by early menopause.
Effect of obesity on vasomotor symptoms
The link between obesity
and the severity of vasomotor symptoms is debatable. There are two opposing
explanations that explain the relationship. The "theromoregulatory" model
proposes that higher BMI and adiposity are associated with a higher prevalence
of hot flashes because body adipose tissue acts as a thermal insulator,
impeding heat dissipation, and the "thin hypothesis" proposes that
women with excess body weight experience fewer VMS because the cytochrome P450
aromatase enzyme in fat tissue converts androgens to estrogens. increased BMI
is connected with a lower incidence of hot flashes during menopause due to
increased levels of estrone, which may lessen hot flash frequency.
Effect
of menopause on obesity
Obesity is associated with a decrease
in circulating estrogen (i.e., estradiol) levels during menopause. Among
premenopausal women, estrogen levels are inversely related to obesity. E2
influences many energy homeostasis pathways, including central nervous system
(CNS) control of food intake and energy expenditure, regulation of lipid
storage and metabolism in adipose tissue, and insulin sensitivity. Experiments with laboratory animals (e.g.,
estrogen receptor knockout and knock-in models, as well as ovariectomy with and
without hormone supplementation) have shown that, in the absence of estrogens,
a general mechanism for fat gain operates by lowering metabolic rate at rest,
decreasing spontaneous physical activity, and increasing caloric intake.
Not only does the menopause facilitate
weight gain, it modifies the pattern of fat distribution. Ovarian estrogens
promote peripheral fat storage in the gluteal and femoral subcutaneous region,
whereas androgens (mainly bioavailable testosterone) stimulate visceral
abdominal fat accumulation. This is irrespective of age, race, total fat mass,
and other cardiovascular risk factors and changes following the menopause.
Menopause
and cardio-metabolic risk
Abdominal fat is recognized as a
metabolically active endocrine organ that secretes numerous adipokines and
substances linked to insulin resistance, type 2 diabetes, and metabolic
syndrome. Alterations in adipokine release from visceral fat initiate
inflammation and play a role in insulin resistance, leading to elevated levels
of circulating insulin .
Because most VAT is drained by the
portal vein, the hyperlipolytic state of large (hypertrophic) adipocytes
associated with visceral obesity exposes the liver to high concentrations of
free fatty acids and glycerol, leading to several impairments in liver
metabolism, such as reduced hepatic extraction of insulin (exacerbating hyperinsulinemia)
and increased production of triglyceride-rich lipoproteins, as well as
increased production of hepatic glucose, which explains the link between
visceral obesity and glucose intolerance and type 2 diabetes .
Obesity
and osteoporosis:
The notion that obesity has a
protective effect against fractures has influenced clinical practice, with BMI
being a component of the Fracture Risk Assessment Tool (FRAX). Research has
shown a positive correlation between bone mineral density (BMD) and BMI, as
well as a lower incidence of hip fractures in adults with obesity . A
systematic review and meta-analysis of 121 studies found higher BMD in the
lumbar spine, total hip, femoral neck, and radius in men and women with obesity
compared to their counterparts with normal weight.
Menopausal
obesity and risk of cancer:
Obesity after menopause, particularly
visceral adiposity, increases the risk of developing breast cancer. Many
studies have revealed that postmenopausal women who accumulate abdominal fat
tissue are more likely to develop breast cancer. The risk of postmenopausal
breast cancer rises by 11% for every 5 kilograms added as an adult. Overweight
or obese women have a 1.5-2 times increased risk of postmenopausal estrogen
receptor positive (ERþ) and progesterone receptor-positive breast cancer, with
an increase of 70% for ER þ breast cancer.
Management
of menopause and related obesity:
Obesity management consists of
lifestyle changes, as well as pharmaceutical and nonpharmacological
interventions. Non-pharmacological treatments for managing grade I obesity
include a low-calorie diet and increased physical exercise. Pharmacological
therapy is indicated for patients who are unable to meet their weight loss
objectives using these methods. Indications for grade II and grade III obesity
include personalized pharmacological and surgical recommendations.
Lifestyle
changes and exercise:
Lifestyle changes, such as regular physical activity and
dietary management, have a positive effect and prevention of metabolic
diseases. Intensive lifestyle changes leading to weight loss have been shown to
reduce various menopausal symptoms.
Recommended activities for menopausal
women
Step
I: Aging makes the body less
flexible. Start with warm‑up exercises such as full body stretches, walking for
10 min on the treadmill, suryanamaskar, etc. Warming up helps to prepare the
body for exercise by gradually increasing physical activity, joint mobility,
and stretching.
Step
II : Aerobic exercises help to burn
calories and provide cardiometabolic benefits to older women. Aerobic exercise
can be initiated by walking for a short duration at a comfortable pace.
Step
III : Short bouts of resistance exercise
and strength training can also be incorporated using resistance bands, weight
resistance, or utilizing one’s own body weight. It is recommended that these
exercises can be incorporated on every alternate day focusing on the abdomen,
arms, legs, shoulders, and hips.
Step
IV: Practicing yoga and stretches help
to maintain flexibility in older age women to perform daily chores. These light
intensity exercise do not spike the vasomotor symptoms and help to ease the
psychological symptoms.
Step
V : Balance exercises help in postural
and gait control to prevent falls in menopausal women. Practices such as tai
chi, pilates, and some functional exercises Can help to maintain balance
Step
VI :The exercise session should
conclude with cooling down exercises such as walking a few minutes and muscle
relaxing postures and stretches which will ease the pain. Regular exercise has
both short‑term and long‑term benefits in menopausal women .
Strength
training: Due to the strong
influence of aging and the menopause on body composition, including the loss of
lean mass, exercise designed to improve and maintain muscle mass is critical.
In this regard, strength training has been the focus of some studies examining
how exercise may mitigate metabolic dysfunction following the menopause. A
study investigating the association of resistance training exercise frequency
and volume with changes in body composition among postmenopausal women found
that resistance training was successful in preventing weight gain and
deleterious changes in body composition.
High-intensity
interval training: The metabolic
benefits of high intensity interval training (HIIT) are well established. A
recent meta-analysis concluded that HIIT is a time-efficient, feasible, and
effective intervention to modify body composition by reducing abdominal and
visceral fat mass . Lean mass increases the basal metabolic rate and total
energy expenditure, so the combination of HIIT and resistance training may be
an equally beneficial exercise modality for postmenopausal women .
v Dietary strategies for weight loss:
1.Based on amount of food intake :
Low calorie diet |
Consumption of 1,000–1,500 calories
and deficit of 500–750 calories per day. Recommended as the initial strategy |
Very low calorie diet |
Consumption of 600–900 calories per
day. Can be maintained for a relatively short time period of time (2 weeks to
3 months), followed by a gradual switch to a low-calorie diet. Considered for
severe obesity, sarcopenic obesity, obesity associated with type 2 diabetes,
hypertriglyceridemia, and hypertension |
Meal replacements |
Useful for controlling calories
without placing much effort on calorie calculation or meal planning May
include either total or partial meal replacements (one or two meals a day) |
Low fat diet |
Consumption of fat as < 15%–20% of
daily calories, especially saturated fatty acids as < 7%–10%.Mostly
plant-based meals |
Low carbohydrate diet |
Consumption of carbohydrates as <
45% of daily calories or < 130 mg/day. Recommended as a dietary strategy
for type 2 diabetes. Might be useful for initial weight loss, but long-term
results are similar to following a low-fat diet. |
Ketogenic diet |
Consumption of carbohydrates as <
10% of daily calories or < 50 mg/day. May decrease appetite, but long-term
safety is unknown |
High protein diet |
Increase protein intake to 30% of
total daily calories or 1–1.2 g/kg of ideal body weight. Useful in
maintaining weight loss and increasing satiety. High-protein diets from
animal sources should be handled with caution for people with risk of chronic
kidney disease. |
Mediterranean diet |
Consists of high consumption of
fruits and vegetables, poultry, fish, dairy products, and monounsaturated
fats, with little to no consumption of red meat. Helpful in improving
cardiometabolic parameters and cognitive function. |
Intermittent fasting :Intermittent fasting involves regular periods with no or very limited calorie intake. The three most widely used regimens are alternate-day fasting, 5:2 intermittent fasting (fasting or consuming 900–1,000 calories for 2 days each week), and daily timerestricted feeding (fasting for 16–18 hours a day). The benefits of intermittent fasting come not only from reduction in calorie intake, but also from its effects on metabolic switching to reverse insulin resistance, strengthen the immune system, and enhance physical and cognitive function.
Behavioral therapy: Behavioral therapy is a set of strategies, which includes goal setting, problem‑solving, emotional eating, stimulus control, and relapse prevention. These strategies aim to better patient’s adherence to dietary and exercise regimens.
Pharmacological
treatment:
· Menopausal
Hormone Therapy (MHT): It is a recommended
treatment option for women experiencing menopausal symptoms, particularly
vasomotor symptoms (VMS). MHT should be
individualized based on women's needs, symptoms, and clinical conditions. It is
essential to consider the best type, route, dose, and duration of MHT, taking
into account factors such as efficacy, tolerability, adherence, and any other
relevant aspects . This individualized approach can help ensure that women
receive the most appropriate and effective treatment for their menopausal
symptoms. When prescribing (MHT), it is
important to consider obesity due to the endocrine nature of adipose tissue,
which produces estrogens and is linked to conditions like the metabolic
syndrome.
While
MHT has demonstrated benefits in reducing cardiovascular risk, osteoporosis,
bone fractures, improving genitourinary syndrome of menopause, and enhancing
quality of life, it should not be prescribed solely for preventive purposes .
· Anti-Obesity
Drugs: In Asian Indians, pharmacotherapy should
be initiated along with lifestyle modifications in individuals with a BMI
>27 kg/m2 or in individuals with a BMI >25 kg/m2 with at least one
associated comorbid medical condition such as hypertension, dyslipidemia, type
2 diabetes (T2DM), and obstructive sleep apnea. A higher cutoff of BMI >30
kg/m2 or >27 kg/m2 with comorbidities are endorsed by western guidelines .
Pharmacotherapy
presently approved includes orlistat, phentermine and topiramate comibination,
Liraglutide and semaglutide.
Bariatric (metabolic) surgery: It is a complementary method of treating obesity in the case of ineffective behavioral treatment and pharmacotherapy. Among the many available surgical methods, such as Roux-en-Y gastric bypass, biliopancreatic diversion with duodenal switch, sleeve gastrectomy, or laparoscopic adjustable gastric banding (LAGB) seem to be associated with high efficacy and a positive result, which largely depends on the experience of the surgeon performing the procedure. On the other hand, maintaining the achieved effect of surgical treatment depends primarily on the patient and the continuation of non-pharmacological and pharmacological methods used by them. According to current guidelines (Endocrine society 2016), indications for bariatric surgery include:
— class 3 obesity (BMI
≥ 40 kg/m2);
— class 2 obesity (BMI
35–39.9 kg/m2), with ≥ 1 obesity related complication
Conclusions:
Menopausal transition is characterized by unfavorable changes in body composition characterized by increase in fat mass and decrease in lean muscle mass. Obesity is a well-known risk factor for CVS disease, metabolic syndrome, and several malignancies. These changes are primarily due to aging or hormonal changes are still a matter of debate. In women with obesity, combined oral MHT should not be the first choice because the evidence shows an increased risk of thromboembolic disease; although the absolute risk, especially in those under 60 years of age, is low. The use of estrogen-only or combined transdermal MHT does not increase the risk of thrombotic events in women with obesity. MHT has been shown to reverse the menopausal transition associated increase in abdominal and visceral adiposity Obesity in women during midlife is a complex and multifaceted issue with significant implications for health and well-being. By understanding the underlying causes, recognizing the impacts and implementing comprehensive strategies for prevention and treatment, we can work towards reducing the prevalence of obesity and improving the overall health outcomes and quality of life for midlife women. Empowering women to make informed choices and providing the necessary support systems are critical steps towards this goal.
References:
1. Ahuja
M. Age of menopause and determinants of menopause age: A PAN India survey by
IMS. J Midlife Health. 2016 Jul-Sep;7(3):126-131.
2. El Khoudary SR, Greendale G, Crawford SL et
al., The menopause transition and women's health at midlife: a progress report
from the Study of Women's Health Across the Nation (SWAN). Menopause. 2019
Oct;26(10):1213-1227.
3. Farahmand
M, Ramezani Tehrani F, Rahmati M, Azizi F. Anthropometric indices and age at
natural menopause: a 15-year follow-up population-based study. Int J Endocrinol
Metabol 2021 Aug 5;19(4).
4. Harlow
SD, Gass M, Hall JE, et al. Executive
summary of the Stages of Reproductive Aging Workshop + 10: addressing the
unfinished agenda of staging reproductive aging. Menopause.2012;19(4):387-395.
5. Nanette
et al, The menopausal transition: Signs, symptoms and management options, The
journal of clinical endocrinology and metabolism,volume 106 ,Issue 1,January
2021,pages 1-15
6. Paramsothy
P, Harlow SD, Nan B, et al. Duration of
the menopausal transition is longer in women with young age at onset: the
multiethnic Study of Women’s Health Across the Nation.
Menopause.2017;24(2):142-149.
7. Li
Y, Zhao D, Wang M, Sun J, Liu J, Qi Y, et al. Association between body mass
index, waist circumference, and age at natural menopause: a population-based
cohort study in Chinese women. Women Health 2021;61(9):902e13.
8. Palacios
S, Chedraui P, Sánchez-Borrego R, Coronado P, Nappi RE. Obesity and menopause.
Gynecol Endocrinol. 2024 Dec;40(1):2312885.
9. Van
Pelt RE, Gavin KM, Kohrt WM. Regulation of body composition and bioenergetics
by estrogens. Endocrinol Metab Clin North Am. 2015;44(3):663–676.
10. Gao
B, Huang Q, Lin YS, et al. Dose-dependent effect of estrogen suppresses the
osteo-adipogenic transdifferentiation of osteoblasts via canonical wnt
signaling pathway. PLoS One. 2014;9(6):e99137.
11. Chen
J, Zhu L, Yao X, et al. The association between abdominal obesity and femoral
neck bone mineral density in older adults. J Orthop Surg Res. 2023;18(1):171.
12. Zuo
Q, Band S, Kesavadas M, Madak Erdogan Z. Obesity and postmenopausal hormone
receptor-positive breast cancer: epidemiology and mechanisms. Endocrine Society
Endocrinology (United States) 2021;162.
13. Heymsfield
SB, Wadden TA. Mechanisms, pathophysiology, and management of obesity. N Engl J
Med 2017;376:254‑66.
14. Maillard,
F.; Pereira, B.; Boisseau, N. Effect of High-Intensity Interval Training on
Total, Abdominal and Visceral Fat Mass: A Meta-Analysis. Sport Med. 2018, 48,
269–288.
15. Grossman,
J.; Arigo, D. Meaningful weight loss in obese postmenopausal women: A pilot
study of high-intensity interval training and wearable technology. Menopause
2018, 25, 465–470.
16. Stuenkel
CA, Davis SR, Gompel A, et al. Treatment of Symptoms of the Menopause: An
Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2015;
100(11): 3975–4011.
17. Vinogradova
Y, Coupland C, Hippisley-Cox J. Use of hormone replacement therapy and risk of
venous thromboembolism: nested case-control studies using the QResearch and
CPRD databases. BMJ. 2019;364:k4810.
18. Wharton
S, Lau DCW, Vallis M, Sharma AM, Biertho L, Campbell-Scherer D, et al. Obesity
in adults:A clinical practice guideline. CMAJ. 2020;19:E875–91.
19. Allison
DB, Gadde KM, Garvey WT, et al. Controlled-release phentermine/topiramate in
severely obese adults: a randomized controlled trial (EQUIP). Obesity (Silver
Spring). 2012;20(2):330– 342.
20. Gadde
KMD, Allison DBP, Ryan DHMD, et al. Effects of low-dose, controlled-release,
phentermine plus topiramate combination on weight and associated comorbidities
in overweight and obese adults (CONQUER): a randomised, placebo-controlled,
phase 3 trial. Lancet. 2011;377(9774):1341–1352.
21. Timothy
Garvey W, Ryan DH, Look M, et al. Two-year sustained weight loss and metabolic
benefits with controlled-release phentermine/topiramate in obese and overweight
adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am
J Clin Nutr. 2012;95(2):297–308.
22. Pi-Sunyer X, Astrup A, Fujioka K, Greenway F,
Halpern A, Krempf M, Lau DC, le Roux CW, Violante Ortiz R, Jensen CB, Wilding
JP; SCALE Obesity and Prediabetes NN8022-1839 Study Group. A Randomized,
Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med.
2015 Jul 2;373(1):11-22.
23. Zhong
P, Zeng H, Huang M, Fu W, Chen Z. Efficacy and safety of once-weekly
semaglutide in adults with overweight or obesity: a meta-analysis. Endocrine.
2022;75(3):718–724.
24. Chakhtoura
M, Haber R, Ghezzawi M, Rhayem C, Tcheroyan R, Mantzoros CS. Pharmacotherapy of
obesity: an update on the available medications and drugs under investigation.
EClinicalMedicine. 2023 Mar 20;58:101882.